<DOC>
	<DOCNO>NCT02509156</DOCNO>
	<brief_summary>The primary purpose study examine safety feasibility deliver allogeneic human mesenchymal stem cell ( allo-MSCs ) transendocardial injection cancer survivor leave ventricular ( LV ) dysfunction secondary anthracycline-induced cardiomyopathy ( AIC ) . The secondary purpose study obtain preliminary evidence therapeutic efficacy allo-MSCs deliver transendocardial injection cancer survivor LV dysfunction secondary AIC .</brief_summary>
	<brief_title>Stem Cell Injection Cancer Survivors</brief_title>
	<detailed_description>This phase I , randomize , placebo-controlled , trial evaluate safety feasibility allo-MSCs administer transendocardial injection thirty-six subject anthracycline-induced cardiomyopathy ( AIC ) . The first six subject receive allo-MSC therapy ( open label ) assess safety feasibility study procedure . Following 1 month data review six subject National Heart , Lung , Blood Institute Gene Cell Therapy Data Safety Monitoring Board ; follow randomized , double-blind clinical trial enrol thirty subject . These thirty subject randomize 1:1 receive allo-MSCs placebo . All subject undergo cardiac catheterization study product administration use NOGA Myostar catheter injection system . Subjects follow 1 day , 1 week , 1 month , 6 month , 12 month post study product injection . All endpoint assess 6 12 month visit occur 180 ±30 day 365 ±30 day , respectively , day study product injection ( Day 0 ) . For purpose safety evaluation endpoint analysis , Investigators utilize `` intention-to-treat '' study population . In addition , phase I study first cell therapy study population , 12 month available standard-of-care medical record cancer surveillance review cancer recurrence .</detailed_description>
	<mesh_term>Cardiomyopathies</mesh_term>
	<criteria>Inclusion Criteria To participate , subject MUST : 1 . Be ≥ 18 &lt; 80 year age 2 . Be cancer survivor diagnosis AIC 3 . Have LVEF ≤ 40 % cMRI 4 . Be NYHA class IIIII 5 . Have receive initial diagnosis AIC least six month earlier stable , optimallytolerated therapy betablockers , ACE inhibitors/ARBs , and/or aldosterone antagonist 1 month , unless contraindicate 6 . Have period least two year clinical cancerfree state* low likelihood recurrence ( fiveyear risk recurrence estimate 30 % less ) , determined oncologist , base tumor type , response therapy , negative metastatic workup time diagnosis ( *exceptions carcinoma situ fully resect basal squamous cell cancer skin . ) 7 . Be candidate cardiac catheterization Exclusion Criteria To participate , subject MUST NOT HAVE : 1 . A life expectancy &lt; 12 month 2 . A CT scan baseline cardiac MRI show new tumor suspicious lymphadenopathy raise concern malignancy 3 . Presence CAD determine via image within 12 month prior study enrollment ( e.g . rest stress nuclear scan ( SPECT/PET/CT ) , stress echocardiogram , stress MRI , cardiac compute tomography angiography ( CCTA ) . If coronary arteriogram , within last 24 month ) 4 . Had previous myocardial infarction 5 . A history radiation therapy AND evidence constrictive physiology and/or evidence pattern nonischemic cardiomyopathy cardiac MRI ( e.g. , amyloidosis , sarcoidosis , hemochromatosis , pure radiationinduced cardiomyopathy , etc . ) consistent AIC dominant etiology heart failure 6 . Valvular heart disease include 1 ) mechanical bioprosthetic heart valve ; 2 ) severe valvular ( valve ) insufficiency/regurgitation within 12 month consent . 7 . Aortic stenosis valve area ≤ 1.5cm2 8 . A history LV reduction surgery cardiomyoplasty 9 . Evidence cardiogenic shock 10 . A history ischemic hemorrhagic stroke within 90 day baseline test 11 . Liver dysfunction baseline testing , evidence enzyme ( e.g. , AST , ALT , alkaline phosphatase ) great 3 time upper limit normal 12 . Diabetes poorly control blood glucose level ( HbA1c &gt; 8.5 % ) 13 . An underlying autoimmune disorder current immunosuppressive therapy ( e.g. , chronic corticosteroid , rheumatologic immune modulate therapy ) likelihood use immunosuppressive therapy participation trial 14 . A baseline eGFR &lt; 35 ml/min/1.73m2 15 . A contrast allergy adequately manage premedication 16 . A history organ cell transplantation , except transplantation bone , skin , ligament , tendon , cornea 17 . A hematologic abnormality baseline test evidence hemoglobin &lt; 9 g/dl ; hematocrit &lt; 30 % ; absolute neutrophil count &lt; 2,000 total WBC count 2 time upper limit normal ; platelet value &lt; 100,000/ul 18 . Evidence active systemic infection time study product delivery 19 . HIV and/or active HBV HCV 20 . Coagulopathy ( INR &gt; 1.5 ) due reversible cause ( e.g. , warfarin and/or Factor Xa inhibitor ) ( see Section 6.4 : injection procedure anticoagulation therapy ) Note : Subjects withdraw anticoagulation exclude . 21 . Presence LV thrombus 22 . Presence pacemaker and/or ICD generator follow limitations/conditions : manufacture year 2000 lead implant &lt; 6 week prior consent nontransvenous epicardial abandon lead subcutaneous ICDs leadless pacemaker condition , judgment devicetrained staff , would deem MRI contraindicate 23 . Pacemakerdependence ICD ( Note : pacemakerdependent candidate without ICD exclude ) 24 . A cardiac resynchronization therapy ( CRT ) device implant &lt; 3 month prior consent 25 . Other MRI contraindication ( e.g . patient body habitus incompatible MRI ) 26 . An appropriate ICD fire antitachycardia pace ( ATP ) ventricular fibrillation ventricular tachycardia within 30 day consent 27 . Ventricular tachycardia ≥ 20 consecutive beat without ICD within 3 month consent , symptomatic Mobitz II high degree atrioventricular block without function pacemaker within 3 month consent 28 . A history drug abuse ( use illegal `` street '' drug except marijuana , prescription medication use appropriately preexist medical condition ) alcohol abuse ( ≥ 5 drinks/day ˃ 3 month ) , document medical , occupational , legal problem arise use alcohol drug within past 24 month 29 . Cognitive language barrier prohibit obtain inform consent study element ( interpreter permit ) 30 . Participation ( currently within previous 30 day ) cardiac relate investigational therapeutic ( include stem cell base therapy ) device trial 31 . Pregnancy , lactation , plan become pregnant next 12 month , unwilling use acceptable form birth control study participation 32 . Any condition , judgment Investigator Sponsor , would contraindication enrollment , study product administration , followup</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Cardiomyopathy</keyword>
	<keyword>AIC</keyword>
	<keyword>Anthracyclines</keyword>
	<keyword>Chemotherapy</keyword>
	<keyword>Allogeneic</keyword>
	<keyword>Mesenchymal stem cell</keyword>
	<keyword>MSCs</keyword>
	<keyword>Cancer survivor</keyword>
	<keyword>Breast Cancer</keyword>
	<keyword>Leukemia</keyword>
	<keyword>Lymphoma</keyword>
	<keyword>Sarcoma</keyword>
</DOC>